pharma
AstraZeneca shocked as inhaler fails to outclass GSK rival in COPD
August 23, 2018Research and Development AstraZeneca, COPD, GSK, anoro, inhaler, pharma
Researchers at AstraZeneca have been left scratching their heads as new Phase 3b results for its inhaler, Bevespi Aerosphere, posted …
Novartis’ investigational combo impresses in breast cancer sub-group
August 23, 2018Research and Development Cancer, Novartis, breast cancer, fulvestrant, pharma
Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment …
FDA refuses Allergan’s uterine bleeding therapy with a request for more data
August 22, 2018Research and Development, Sales and Marketing Allergan, Esmya, FDA, pharma
Allergan has shared the news that the FDA has refused to award marketing authorisation to its ulipristal acetate product Esmya …
Blockchain deployed in fight against fake pharmaceuticals in India
August 22, 2018Research and Development India, NITI, blockchain, pharma, technology
Indian policymakers in collaboration with an Indian hospital chain and an American multinational, have initiated plans to deploy blockchain technology …
Novo’s semaglutide hits the mark in Phase 3 type 2 diabetes study
August 21, 2018Manufacturing and Production, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes
Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of …
Japan approves AstraZeneca’s Tagrisso in EGFRm non-small cell lung cancer
August 21, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Japan, Tagrisso, lung cancer, pharma
AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry …
Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration
August 20, 2018Sales and Marketing Bayer, Eylea, FDA, Regeneron, US, pharma
Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the …
Gilead CMO announces departure alongside two new exec appointments
August 17, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma
Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the …
FDA approves first-ever generic EpiPen versions, courtesy of Teva
August 17, 2018Medical Communications, Sales and Marketing FDA, Mylan, Teva, US, epipen, pharma
The FDA has announced the approval of the first generic versions of Mylan’s EpiPen and EpiPen Jr epinephrine auto-injectors as …
Genentech to axe 223 staff from San Francisco HQ
August 17, 2018Manufacturing and Production, Medical Communications Genentech, Roche, layoffs, pharma
Roche subsidiary Genentech has announced plans to axe 223 employees from its headquarters in San Francisco, California, beginning on 31 …
“Triple pill” blood pressure combo proves more effective, safe than standard care
August 16, 2018Research and Development blood pressure, heart attack, heart disease, pharma, triple pill
A “triple pill” combining three established and effective drugs at low dosage levels could prove much more effective in treating …
Pfizer partners up with BioNTech for $425m to pursue mRNA flu vaccines
August 16, 2018Research and Development BioNTech, Pfizer, Vaccine, flu, influenza, pharma
Pfizer has announced a partnership with German biotech firm BioNTech after signing a multi-year deal worth $425 million to develop …
Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care
August 15, 2018Research and Development HIV, Janssen, ViiV Healthcare, pharma
Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, …
Gilead CMO announces departure alongside two new exec appointments
August 15, 2018Medical Communications, Research and Development Gilead, pharma
Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the …
NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay
August 14, 2018Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy
UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
